CJ-13,610 hydrochloride is an orally active nonredox-type inhibitor of 5-LOX and can be used in studies about the prevention of untoward pathophysiological effects of LTs.
In intact human polymorphonuclear leukocytes (PMNL), challenged with the Ca(2+)-ionophore A23187, CJ-13,610 hydrochloride potently suppressed 5-LOX product formation with an IC50 of 70 nM. In transfected HeLa cells, CJ-13,610 hydrochloride only slightly discriminated between phosphorylatable wild-type 5-LOX and a 5-LOX mutant that lacks phosphorylation sites[2].